Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00638703 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients
A Phase 2 study, sponsored by OxThera.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT00638703 is a Phase 2 study that has completed, run by OxThera. The registered enrollment target is 43 participants.
The verdict
NCT00638703, a Phase 2 study, has completed, sponsored by OxThera.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine if Oxalobacter formigenes is effective at lowering urinary oxalate levels in patients with primary hyperoxaluria.
Interventions
- DRUG Placebo
- BIOLOGICAL Oxalobacter formigenes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00638703
The ClinicalTrials.gov registry entry for NCT00638703 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OxThera, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00638703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00638703 about?
NCT00638703 is a clinical study titled "Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients". The main purpose of this study is to determine if Oxalobacter formigenes is effective at lowering urinary oxalate levels in patients with primary hyperoxaluria.
What is the current status of trial NCT00638703?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2007-10. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00638703?
The interventions under investigation include: Placebo (DRUG), Oxalobacter formigenes (BIOLOGICAL).
Who is sponsoring clinical trial NCT00638703?
This trial is sponsored by OxThera, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.